Circumventing cancer drug resistance in the era of personalized medicine

All successful cancer therapies are limited by the development of drug resistance. The increase in the understanding of the molecular and biochemical bases of drug efficacy has also facilitated studies elucidating the mechanism(s) of drug resistance. Experimental approaches that can help predict the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer discovery 2012-03, Vol.2 (3), p.214-226
Hauptverfasser: Garraway, Levi A, Jänne, Pasi A
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 226
container_issue 3
container_start_page 214
container_title Cancer discovery
container_volume 2
creator Garraway, Levi A
Jänne, Pasi A
description All successful cancer therapies are limited by the development of drug resistance. The increase in the understanding of the molecular and biochemical bases of drug efficacy has also facilitated studies elucidating the mechanism(s) of drug resistance. Experimental approaches that can help predict the eventual clinical drug resistance, coupled with the evolution of systematic genomic and proteomic technologies, are rapidly identifying novel resistance mechanisms. In this review, we provide a historical background on drug resistance and a framework for understanding the common ways by which cancers develop resistance to targeted therapies. We further discuss advantages and disadvantages of experimental strategies that can be used to identify drug resistance mechanism(s). Increased knowledge of drug resistance mechanisms will aid in the development of effective therapies for patients with cancer. We provide a summary of current knowledge on drug resistance mechanisms and experimental strategies to identify and study additional drug resistance pathways.
doi_str_mv 10.1158/2159-8290.CD-12-0012
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1013919897</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1013919897</sourcerecordid><originalsourceid>FETCH-LOGICAL-c470t-6a91a3808293eb59fecc0b985b50df126634c520caf052337e3706f4d0c308ef3</originalsourceid><addsrcrecordid>eNo9kMtOwzAQRS0Eoqj0DxDykk3K2I6TeIlSoEiV2MDacpxxMUqTYidI8PUkaulsZnR153UIuWGwZEwW95xJlRRcwbJcJYwnAIyfkauTfH6q83RGFjF-whipSiXkl2TGuSykUuKKrEsf7LD7xrb37ZZa01oMtA7DlgaMPvaTQH1L-w-kGAztHN1jiF1rGv-LNd1h7a1v8ZpcONNEXBzznLw_Pb6V62Tz-vxSPmwSm-bQJ5lRzIgCxiMFVlI5tBYqVchKQu0YzzKRWsnBGgeSC5GjyCFzaQ1WQIFOzMndYe4-dF8Dxl7vfLTYNKbFboiaAROKqULlozU9WG3oYgzo9D74nQk_o0lPGPXESE-8dLnSjOsJ49h2e9wwVON3p6Z_aOIPIn5s6w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1013919897</pqid></control><display><type>article</type><title>Circumventing cancer drug resistance in the era of personalized medicine</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>American Association for Cancer Research</source><creator>Garraway, Levi A ; Jänne, Pasi A</creator><creatorcontrib>Garraway, Levi A ; Jänne, Pasi A</creatorcontrib><description>All successful cancer therapies are limited by the development of drug resistance. The increase in the understanding of the molecular and biochemical bases of drug efficacy has also facilitated studies elucidating the mechanism(s) of drug resistance. Experimental approaches that can help predict the eventual clinical drug resistance, coupled with the evolution of systematic genomic and proteomic technologies, are rapidly identifying novel resistance mechanisms. In this review, we provide a historical background on drug resistance and a framework for understanding the common ways by which cancers develop resistance to targeted therapies. We further discuss advantages and disadvantages of experimental strategies that can be used to identify drug resistance mechanism(s). Increased knowledge of drug resistance mechanisms will aid in the development of effective therapies for patients with cancer. We provide a summary of current knowledge on drug resistance mechanisms and experimental strategies to identify and study additional drug resistance pathways.</description><identifier>ISSN: 2159-8274</identifier><identifier>EISSN: 2159-8290</identifier><identifier>DOI: 10.1158/2159-8290.CD-12-0012</identifier><identifier>PMID: 22585993</identifier><language>eng</language><publisher>United States</publisher><subject>Antineoplastic Agents - therapeutic use ; Drug Resistance, Neoplasm ; Humans ; Neoplasms - drug therapy ; Neoplasms - genetics ; Neoplasms - metabolism ; Precision Medicine - methods</subject><ispartof>Cancer discovery, 2012-03, Vol.2 (3), p.214-226</ispartof><rights>2012 AACR.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c470t-6a91a3808293eb59fecc0b985b50df126634c520caf052337e3706f4d0c308ef3</citedby><cites>FETCH-LOGICAL-c470t-6a91a3808293eb59fecc0b985b50df126634c520caf052337e3706f4d0c308ef3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3342,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22585993$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Garraway, Levi A</creatorcontrib><creatorcontrib>Jänne, Pasi A</creatorcontrib><title>Circumventing cancer drug resistance in the era of personalized medicine</title><title>Cancer discovery</title><addtitle>Cancer Discov</addtitle><description>All successful cancer therapies are limited by the development of drug resistance. The increase in the understanding of the molecular and biochemical bases of drug efficacy has also facilitated studies elucidating the mechanism(s) of drug resistance. Experimental approaches that can help predict the eventual clinical drug resistance, coupled with the evolution of systematic genomic and proteomic technologies, are rapidly identifying novel resistance mechanisms. In this review, we provide a historical background on drug resistance and a framework for understanding the common ways by which cancers develop resistance to targeted therapies. We further discuss advantages and disadvantages of experimental strategies that can be used to identify drug resistance mechanism(s). Increased knowledge of drug resistance mechanisms will aid in the development of effective therapies for patients with cancer. We provide a summary of current knowledge on drug resistance mechanisms and experimental strategies to identify and study additional drug resistance pathways.</description><subject>Antineoplastic Agents - therapeutic use</subject><subject>Drug Resistance, Neoplasm</subject><subject>Humans</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - genetics</subject><subject>Neoplasms - metabolism</subject><subject>Precision Medicine - methods</subject><issn>2159-8274</issn><issn>2159-8290</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kMtOwzAQRS0Eoqj0DxDykk3K2I6TeIlSoEiV2MDacpxxMUqTYidI8PUkaulsZnR153UIuWGwZEwW95xJlRRcwbJcJYwnAIyfkauTfH6q83RGFjF-whipSiXkl2TGuSykUuKKrEsf7LD7xrb37ZZa01oMtA7DlgaMPvaTQH1L-w-kGAztHN1jiF1rGv-LNd1h7a1v8ZpcONNEXBzznLw_Pb6V62Tz-vxSPmwSm-bQJ5lRzIgCxiMFVlI5tBYqVchKQu0YzzKRWsnBGgeSC5GjyCFzaQ1WQIFOzMndYe4-dF8Dxl7vfLTYNKbFboiaAROKqULlozU9WG3oYgzo9D74nQk_o0lPGPXESE-8dLnSjOsJ49h2e9wwVON3p6Z_aOIPIn5s6w</recordid><startdate>201203</startdate><enddate>201203</enddate><creator>Garraway, Levi A</creator><creator>Jänne, Pasi A</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201203</creationdate><title>Circumventing cancer drug resistance in the era of personalized medicine</title><author>Garraway, Levi A ; Jänne, Pasi A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c470t-6a91a3808293eb59fecc0b985b50df126634c520caf052337e3706f4d0c308ef3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Antineoplastic Agents - therapeutic use</topic><topic>Drug Resistance, Neoplasm</topic><topic>Humans</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - genetics</topic><topic>Neoplasms - metabolism</topic><topic>Precision Medicine - methods</topic><toplevel>online_resources</toplevel><creatorcontrib>Garraway, Levi A</creatorcontrib><creatorcontrib>Jänne, Pasi A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer discovery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Garraway, Levi A</au><au>Jänne, Pasi A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Circumventing cancer drug resistance in the era of personalized medicine</atitle><jtitle>Cancer discovery</jtitle><addtitle>Cancer Discov</addtitle><date>2012-03</date><risdate>2012</risdate><volume>2</volume><issue>3</issue><spage>214</spage><epage>226</epage><pages>214-226</pages><issn>2159-8274</issn><eissn>2159-8290</eissn><abstract>All successful cancer therapies are limited by the development of drug resistance. The increase in the understanding of the molecular and biochemical bases of drug efficacy has also facilitated studies elucidating the mechanism(s) of drug resistance. Experimental approaches that can help predict the eventual clinical drug resistance, coupled with the evolution of systematic genomic and proteomic technologies, are rapidly identifying novel resistance mechanisms. In this review, we provide a historical background on drug resistance and a framework for understanding the common ways by which cancers develop resistance to targeted therapies. We further discuss advantages and disadvantages of experimental strategies that can be used to identify drug resistance mechanism(s). Increased knowledge of drug resistance mechanisms will aid in the development of effective therapies for patients with cancer. We provide a summary of current knowledge on drug resistance mechanisms and experimental strategies to identify and study additional drug resistance pathways.</abstract><cop>United States</cop><pmid>22585993</pmid><doi>10.1158/2159-8290.CD-12-0012</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2159-8274
ispartof Cancer discovery, 2012-03, Vol.2 (3), p.214-226
issn 2159-8274
2159-8290
language eng
recordid cdi_proquest_miscellaneous_1013919897
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; American Association for Cancer Research
subjects Antineoplastic Agents - therapeutic use
Drug Resistance, Neoplasm
Humans
Neoplasms - drug therapy
Neoplasms - genetics
Neoplasms - metabolism
Precision Medicine - methods
title Circumventing cancer drug resistance in the era of personalized medicine
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T22%3A42%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Circumventing%20cancer%20drug%20resistance%20in%20the%20era%20of%20personalized%20medicine&rft.jtitle=Cancer%20discovery&rft.au=Garraway,%20Levi%20A&rft.date=2012-03&rft.volume=2&rft.issue=3&rft.spage=214&rft.epage=226&rft.pages=214-226&rft.issn=2159-8274&rft.eissn=2159-8290&rft_id=info:doi/10.1158/2159-8290.CD-12-0012&rft_dat=%3Cproquest_cross%3E1013919897%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1013919897&rft_id=info:pmid/22585993&rfr_iscdi=true